We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$194M
Cap. Flow %
-10.46%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.69%
2 Healthcare 6.69%
3 Materials 0.25%
4 Financials 0.16%
5 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVM icon
226
CEL-SCI Corp
CVM
$26M
$154K 0.01%
2,400
-6,080
-72% -$485K
PTCT icon
227
CALL
PTC Therapeutics
PTCT
$5.48B
$151K 0.01%
153
-5,787
-97% -$70K
NUROW
228
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
$148K 0.01%
36,840
-882
-2% -$3.79K
IOVA icon
229
CALL
Iovance Biotherapeutics
IOVA
$4.24B
$145K 0.01%
195
– –
CMRX
230
DELISTED
Chimerix, Inc.
CMRX
$135K 0.01%
21,200
-58,700
-73% -$333K
CYTO
231
DELISTED
Altamira Therapeutics Ltd
CYTO
$133K 0.01%
+2
New +$160K
DVAX
232
PUT
DELISTED
Dynavax Technologies
DVAX
$130K 0.01%
219
-39
-15% -$188
RXDX
233
CALL
DELISTED
Ignyta, Inc.
RXDX
$123K 0.01%
+143
New +$1.04K
MBRX icon
234
Moleculin Biotech
MBRX
$14.6M
$117K 0.01%
+44
New +$154K
PALI icon
235
PUT
Palisade Bio
PALI
$351M
– –
0
– –
IMUC.WS
236
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
$113K 0.01%
418,767
+35,296
+9% +$18.5K
RNVAZ
237
DELISTED
Rennova Health, Inc. Warrant
RNVAZ
$105K 0.01%
5,249,822
+323,809
+7% +$8.71K
ABUS icon
238
CALL
Arbutus Biopharma
ABUS
$1B
$102K 0.01%
315
-1,718
-85% -$4.77K
OPK icon
239
PUT
Opko Health
OPK
$1.17B
$101K 0.01%
126
-2,149
-94% -$18.1K
FOMX
240
CALL
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$91K ﹤0.01%
184
-697
-79% -$6.71K
GNMX
241
CALL
DELISTED
Aevi Genomic Medicine Inc
GNMX
$84K ﹤0.01%
+450
New +$2.04K
LRMR icon
242
CALL
Larimar Therapeutics
LRMR
$406M
$69K ﹤0.01%
+12
New +$596
OREX
243
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$68K ﹤0.01%
+197
New +$778
OASM
244
DELISTED
Oasmia Pharmaceutical AB
OASM
$66K ﹤0.01%
+35,054
New +$82.2K
CANF
245
Can-Fite BioPharma American Depositary Shares
CANF
$4.8M
$57K ﹤0.01%
+10
New +$60.7K
CHRN
246
PUT
ChronoScale Holdings
CHRN
$2.6B
$53K ﹤0.01%
+1
New +$852
IPCI
247
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$51K ﹤0.01%
+2,041
New +$52.6K
CSCI
248
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$50K ﹤0.01%
2
-4
-67% -$1.18K
RNVA
249
DELISTED
Rennova Health, Inc.
RNVA
$45K ﹤0.01%
1,666
-2,828
-63% -$93.2K
VCEL icon
250
Vericel Corp
VCEL
$2.03B
$41K ﹤0.01%
14,694
-135,206
-90% -$382K
8 9
10
11 12

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $194M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 81% a quarter earlier, followed by Healthcare and Materials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.